Significantly elevated concentration of plasma monocyte chemotactic protein 1 of patients with pelvic inflammatory disease

Pei Ching Hsiao, Po H. Wang, Yi Torng Tee, Shun F. Yang, Pen H. Su, Yi Chen Chen, Long Y. Lin, Hsiu Ting Tsai

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Our goal was to compare the expression of plasma monocyte chemotactic protein 1 (MCP-1) and the gene polymorphism in patients with pelvic inflammatory disease (PID) and healthy controls. The enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) were, respectively, used to measure the plasma MCP-1 level and MCP-1 polymorphism in 70 healthy controls and in 64 patients with PID before and after they received routine treatment protocols. We found plasma MCP-1 was significantly elevated in patients with PID compared to that in normal controls and decreased significantly compared to that in patients with PID after they received treatment. The increased expression of plasma MCP-1 was significantly correlated with the cell counts of white blood cells (WBCs) in blood and the level of plasma C-reactive protein (CRP) of patients with PID before they received treatment. There was no association between MCP-1 -2518G/A SNP and its gene expression levels and PID susceptibility. Elevated plasma MCP-1 could be a biological marker for the diagnosis and to be a new strategy for target therapy of pelvic inflammatory disease.

Original languageEnglish
Pages (from-to)549-555
Number of pages7
JournalReproductive Sciences
Volume17
Issue number6
DOIs
Publication statusPublished - Jun 2010
Externally publishedYes

Fingerprint

Pelvic Inflammatory Disease
Chemokine CCL2
Blood Proteins
Disease Susceptibility
Clinical Protocols
Leukocyte Count
Restriction Fragment Length Polymorphisms
C-Reactive Protein
Single Nucleotide Polymorphism
Therapeutics
Cell Count
Biomarkers
Enzyme-Linked Immunosorbent Assay
Gene Expression
Polymerase Chain Reaction
Genes

Keywords

  • Monocyte chemotactic protein 1
  • Pelvic inflammatory disease
  • Single nucleotide polymorphism

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Significantly elevated concentration of plasma monocyte chemotactic protein 1 of patients with pelvic inflammatory disease. / Hsiao, Pei Ching; Wang, Po H.; Tee, Yi Torng; Yang, Shun F.; Su, Pen H.; Chen, Yi Chen; Lin, Long Y.; Tsai, Hsiu Ting.

In: Reproductive Sciences, Vol. 17, No. 6, 06.2010, p. 549-555.

Research output: Contribution to journalArticle

Hsiao, Pei Ching ; Wang, Po H. ; Tee, Yi Torng ; Yang, Shun F. ; Su, Pen H. ; Chen, Yi Chen ; Lin, Long Y. ; Tsai, Hsiu Ting. / Significantly elevated concentration of plasma monocyte chemotactic protein 1 of patients with pelvic inflammatory disease. In: Reproductive Sciences. 2010 ; Vol. 17, No. 6. pp. 549-555.
@article{ebb21787532d45789e0755dcf5d001fa,
title = "Significantly elevated concentration of plasma monocyte chemotactic protein 1 of patients with pelvic inflammatory disease",
abstract = "Our goal was to compare the expression of plasma monocyte chemotactic protein 1 (MCP-1) and the gene polymorphism in patients with pelvic inflammatory disease (PID) and healthy controls. The enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) were, respectively, used to measure the plasma MCP-1 level and MCP-1 polymorphism in 70 healthy controls and in 64 patients with PID before and after they received routine treatment protocols. We found plasma MCP-1 was significantly elevated in patients with PID compared to that in normal controls and decreased significantly compared to that in patients with PID after they received treatment. The increased expression of plasma MCP-1 was significantly correlated with the cell counts of white blood cells (WBCs) in blood and the level of plasma C-reactive protein (CRP) of patients with PID before they received treatment. There was no association between MCP-1 -2518G/A SNP and its gene expression levels and PID susceptibility. Elevated plasma MCP-1 could be a biological marker for the diagnosis and to be a new strategy for target therapy of pelvic inflammatory disease.",
keywords = "Monocyte chemotactic protein 1, Pelvic inflammatory disease, Single nucleotide polymorphism",
author = "Hsiao, {Pei Ching} and Wang, {Po H.} and Tee, {Yi Torng} and Yang, {Shun F.} and Su, {Pen H.} and Chen, {Yi Chen} and Lin, {Long Y.} and Tsai, {Hsiu Ting}",
year = "2010",
month = "6",
doi = "10.1177/1933719110362593",
language = "English",
volume = "17",
pages = "549--555",
journal = "Reproductive Sciences",
issn = "1933-7191",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Significantly elevated concentration of plasma monocyte chemotactic protein 1 of patients with pelvic inflammatory disease

AU - Hsiao, Pei Ching

AU - Wang, Po H.

AU - Tee, Yi Torng

AU - Yang, Shun F.

AU - Su, Pen H.

AU - Chen, Yi Chen

AU - Lin, Long Y.

AU - Tsai, Hsiu Ting

PY - 2010/6

Y1 - 2010/6

N2 - Our goal was to compare the expression of plasma monocyte chemotactic protein 1 (MCP-1) and the gene polymorphism in patients with pelvic inflammatory disease (PID) and healthy controls. The enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) were, respectively, used to measure the plasma MCP-1 level and MCP-1 polymorphism in 70 healthy controls and in 64 patients with PID before and after they received routine treatment protocols. We found plasma MCP-1 was significantly elevated in patients with PID compared to that in normal controls and decreased significantly compared to that in patients with PID after they received treatment. The increased expression of plasma MCP-1 was significantly correlated with the cell counts of white blood cells (WBCs) in blood and the level of plasma C-reactive protein (CRP) of patients with PID before they received treatment. There was no association between MCP-1 -2518G/A SNP and its gene expression levels and PID susceptibility. Elevated plasma MCP-1 could be a biological marker for the diagnosis and to be a new strategy for target therapy of pelvic inflammatory disease.

AB - Our goal was to compare the expression of plasma monocyte chemotactic protein 1 (MCP-1) and the gene polymorphism in patients with pelvic inflammatory disease (PID) and healthy controls. The enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) were, respectively, used to measure the plasma MCP-1 level and MCP-1 polymorphism in 70 healthy controls and in 64 patients with PID before and after they received routine treatment protocols. We found plasma MCP-1 was significantly elevated in patients with PID compared to that in normal controls and decreased significantly compared to that in patients with PID after they received treatment. The increased expression of plasma MCP-1 was significantly correlated with the cell counts of white blood cells (WBCs) in blood and the level of plasma C-reactive protein (CRP) of patients with PID before they received treatment. There was no association between MCP-1 -2518G/A SNP and its gene expression levels and PID susceptibility. Elevated plasma MCP-1 could be a biological marker for the diagnosis and to be a new strategy for target therapy of pelvic inflammatory disease.

KW - Monocyte chemotactic protein 1

KW - Pelvic inflammatory disease

KW - Single nucleotide polymorphism

UR - http://www.scopus.com/inward/record.url?scp=77952373568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952373568&partnerID=8YFLogxK

U2 - 10.1177/1933719110362593

DO - 10.1177/1933719110362593

M3 - Article

C2 - 20237358

AN - SCOPUS:77952373568

VL - 17

SP - 549

EP - 555

JO - Reproductive Sciences

JF - Reproductive Sciences

SN - 1933-7191

IS - 6

ER -